Search

Your search keyword '"Usmani, Saad Z"' showing total 1,449 results
Start Over Author "Usmani, Saad Z"
1,449 results on '"Usmani, Saad Z"'

201. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Author

Weisel, Katja, primary, Martin, Thomas, additional, Krishnan, Amrita, additional, Jagannath, Sundar, additional, Londhe, Anil, additional, Nair, Sandhya, additional, Diels, Joris, additional, Vogel, Martin, additional, Schecter, Jordan M., additional, Banerjee, Arnob, additional, Berdeja, Jesus G., additional, Nesheiwat, Tonia, additional, Garrett, Ashraf, additional, Qi, Keqin, additional, Valluri, Satish, additional, Usmani, Saad Z., additional, and Yong, Kwee, additional

Published
2021
Full Text
View/download PDF

202. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Author

Bal, Susan, primary, Malek, Ehsan, additional, Kansagra, Ankit, additional, Usmani, Saad Z., additional, Vij, Ravi, additional, Godby, Kelly N., additional, Cornell, Robert F., additional, Kang, Yubin, additional, Umyarova, Elvira, additional, Giri, Smith, additional, Chhabra, Saurabh, additional, Liedtke, Michaela, additional, Callander, Natalie S., additional, Hari, Parameswaran, additional, Kumar, Shaji, additional, and Costa, Luciano J., additional

Published
2021
Full Text
View/download PDF

203. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

Author

Tan, Carlyn Rose, primary, Estrada-Merly, Noel, additional, Landau, Heather, additional, Lekakis, Lazaros, additional, Banerjee, Rahul, additional, Mian, Hira, additional, Usmani, Saad Z., additional, Hanbali, Amr, additional, Lazarus, Hillard M., additional, Kyle, Robert A., additional, Dholaria, Bhagirathbhai, additional, Bal, Susan, additional, Strouse, Christopher, additional, Murthy, Hemant S., additional, Wirk, Baldeep, additional, Nishihori, Taiga, additional, Kumar, Shaji, additional, Shah, Nina, additional, Qazilbash, Muzaffar, additional, and D’Souza, Anita, additional

Published
2021
Full Text
View/download PDF

204. Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)

Author

Costa, Luciano J., primary, Cornell, Robert Frank, additional, Callander, Natalie S., additional, Chhabra, Saurabh, additional, Liedtke, Michaela, additional, Kansagra, Ankit, additional, Godby, Kelly N., additional, Bal, Susan, additional, Giri, Smith, additional, Malek, Ehsan, additional, Kang, Yubin, additional, Vij, Ravi, additional, Usmani, Saad Z., additional, Hari, Parameswaran, additional, and Kumar, Shaji, additional

Published
2021
Full Text
View/download PDF

206. Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Author

Bhutani, Manisha, primary, Robinson, Myra, additional, Atrash, Shebli, additional, Foureau, David M, additional, Rigby, Katherine, additional, Friend, Reed, additional, Paul, Barry, additional, Symanowski, James T, additional, Druhan, Lawrence J, additional, Norek, Sarah, additional, Tucker, Mallory, additional, Pineda-Roman, Mauricio, additional, Voorhees, Peter M., additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

207. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Author

Perrot, Aurore, primary, Facon, Thierry, additional, Kumar, Shaji, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Moreau, Philippe, additional, Bahlis, Nizar J., additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, O'Dwyer, Michael E., additional, Venner, Chris P., additional, Weisel, Katja, additional, Mace, Joseph R., additional, Raje, Noopur S., additional, Tiab, Mourad, additional, Macro, Magaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Liu, Kevin, additional, Fastenau, John, additional, Gries, Katharine S., additional, Ho, Kai Fai, additional, Mistry, Pankaj, additional, Tromp, Brenda, additional, Delioukina, Maria, additional, Vermeulen, Jessica, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

208. Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Author

Chari, Ajai, primary, Hari, Parameswaran, additional, Bahlis, Nizar J., additional, Mateos, Maria-Victoria, additional, van de Donk, Niels W.C.J., additional, Dholaria, Bhagirathbhai, additional, Garfall, Alfred L., additional, Goldschmidt, Hartmut, additional, Kortuem, K. Martin, additional, Krishnan, Amrita Y., additional, Martin, Thomas, additional, Morillo Giles, Daniel, additional, Oriol, Albert, additional, Reece, Donna E., additional, Rodriguez, Cesar, additional, Rodriguez-Otero, Paula, additional, San-Miguel, Jesús F., additional, Usmani, Saad Z., additional, Verona, Raluca I., additional, Wang Lin, Shun Xin, additional, Prior, Thomas J., additional, Wade, Mark, additional, Weiss, Brendan M., additional, Goldberg, Jenna D., additional, and Askari, Elham, additional

Published
2021
Full Text
View/download PDF

209. Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)

Author

Foureau, David M, primary, Bhutani, Manisha, additional, Guo, Fei, additional, Fesenkova, Kateryna, additional, Atrash, Shebli, additional, Friend, Reed, additional, Paul, Barry, additional, Robinson, Myra M, additional, Symanowski, James T, additional, Druhan, Lawrence J, additional, Pineda-Roman, Mauricio, additional, Voorhees, Peter M., additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

210. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Author

Usmani, Saad Z., primary, Kumar, Shaji, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Moreau, Philippe, additional, Bahlis, Nizar J., additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, O'Dwyer, Michael E., additional, Perrot, Aurore, additional, Venner, Chris P., additional, Weisel, Katja, additional, Mace, Joseph R., additional, Raje, Noopur S., additional, Tiab, Mourad, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Pei, Huiling, additional, Van Rampelbergh, Rian, additional, Tromp, Brenda, additional, Delioukina, Maria, additional, and Facon, Thierry, additional

Published
2021
Full Text
View/download PDF

211. Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

Author

Nahi, Hareth, primary, Usmani, Saad Z., additional, Mateos, Maria-Victoria, additional, van de Donk, Niels W.C.J., additional, Moreau, Philippe, additional, Oriol, Albert, additional, Plesner, Torben, additional, Bandyopadhyay, Nibedita, additional, Hellemans, Peter, additional, Tromp, Brenda, additional, Nnane, Ivo, additional, Zemlickis, Donna, additional, Farnsworth, Andrew, additional, and Chari, Ajai, additional

Published
2021
Full Text
View/download PDF

212. Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Author

Dytfeld, Dominik, primary, Dhakal, Binod, additional, Agha, Mounzer, additional, Manier, Salomon, additional, Delforge, Michel, additional, Kuppens, Steven, additional, Afifi, Salma, additional, Deraedt, William, additional, Taraseviciute-Morris, Agne, additional, Schecter, Jordan M., additional, Gilbert, Jane, additional, Yalniz, Fevzi, additional, Florendo, Erika, additional, Pacaud, Lida, additional, Hungria, Vania, additional, Usmani, Saad Z., additional, and Mateos, Maria-Victoria, additional

Published
2021
Full Text
View/download PDF

213. DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Author

Usmani, Saad Z., primary, Alonso Alonso, Aránzazu, additional, Quach, Hang, additional, Koh, Youngil, additional, Guenther, Andreas, additional, Min, Chang-Ki, additional, Zhou, Xiaoou L., additional, Kaisermann, Morrys, additional, Mis, Lukasz M., additional, Williams, Danaè, additional, Yeakey, Anne, additional, Ferron-Brady, Geraldine, additional, Figueroa, David J., additional, Kremer, Brandon E., additional, Gupta, Ira, additional, and Janowski, Wojciech, additional

Published
2021
Full Text
View/download PDF

214. Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

Author

Jakubowiak, Andrzej, primary, Usmani, Saad Z., additional, Berdeja, Jesus G., additional, Agha, Mounzer, additional, Cohen, Adam D, additional, Hari, Parameswaran, additional, Schecter, Jordan M., additional, Madduri, Deepu, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C., additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Zhou, Changwei, additional, Geng, Dong, additional, Pacaud, Lida, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

215. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Author

Moreau, Philippe, primary, Usmani, Saad Z., additional, Garfall, Alfred L., additional, van de Donk, Niels W.C.J., additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Oriol, Albert, additional, Nooka, Ajay K., additional, Martin, Thomas, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar J., additional, Popat, Rakesh, additional, Besemer, Britta, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Verona, Raluca I., additional, Girgis, Suzette, additional, Olyslager, Yunsi, additional, Jaffe, Mindy, additional, Uhlar, Clarissa M., additional, Stephenson, Tara, additional, Van Rampelbergh, Rian, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Kobos, Rachel, additional, and Krishnan, Amrita Y., additional

Published
2021
Full Text
View/download PDF

216. Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Author

Hari, Parameswaran, primary, Berdeja, Jesus G., additional, De Stefano, Valerio, additional, Gay, Francesca, additional, Hooper, Becky, additional, Haltner, Anja, additional, Kumar, Shaji, additional, Martin, Thomas, additional, Mateos, Maria-Victoria, additional, Moreau, Philippe, additional, Rosta, Emily, additional, Samjoo, Imtiaz A., additional, Usmani, Saad Z., additional, Weisel, Katja, additional, Jackson, Carolyn C., additional, Olyslager, Yunsi, additional, Schecter, Jordan M., additional, Vogel, Martin, additional, Garrett, Ashraf, additional, Lee, Sam, additional, Nesheiwat, Tonia, additional, Pacaud, Lida, additional, Zhou, Changwei, additional, Valluri, Satish, additional, Costa, Luciano J., additional, and Lin, Yi, additional

Published
2021
Full Text
View/download PDF

217. Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Author

Perrot, Aurore, primary, Facon, Thierry, additional, Kumar, Shaji, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Moreau, Philippe, additional, Bahlis, Nizar J., additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, O'Dwyer, Michael E., additional, Venner, Chris P., additional, Weisel, Katja, additional, Mace, Joseph R., additional, Raje, Noopur S., additional, Tiab, Mourad, additional, Macro, Magaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Liu, Kevin, additional, Fastenau, John, additional, Gries, Katharine S., additional, Ho, Kai Fai, additional, Mistry, Pankaj, additional, Tromp, Brenda, additional, Delioukina, Maria, additional, Vermeulen, Jessica, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

218. Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Author

Martin, Thomas, primary, Usmani, Saad Z., additional, Berdeja, Jesús G., additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D, additional, Hari, Parameswaran, additional, Avigan, David, additional, Deol, Abhinav, additional, Htut, Myo, additional, Lesokhin, Alexander, additional, Munshi, Nikhil C., additional, O'Donnell, Elizabeth, additional, Stewart, A. Keith, additional, Schecter, Jordan M., additional, Goldberg, Jenna D., additional, Jackson, Carolyn C., additional, Yeh, Tzu-Min, additional, Banerjee, Arnob, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Madduri, Deepu, additional, Olyslager, Yunsi, additional, Zhou, Changwei, additional, Pacaud, Lida, additional, Lin, Yi, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

219. Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Author

Sklavenitis-Pistofidis, Romanos, primary, Dutta, Ankit K., additional, Ujwary, Sylvia, additional, Redd, Robert A., additional, Savell, Alexandra, additional, Fléchon, Léa, additional, Aguet, François, additional, Haradhvala, Nicholas, additional, Zavidij, Oksana, additional, Bustoros, Mark, additional, Tahri, Sabrin, additional, Mouhieddine, Tarek H, additional, Su, Nang K., additional, Ardente, Lily, additional, Anand, Shankara, additional, Rosenblatt, Jacalyn, additional, Zonder, Jeffrey A., additional, Vredenburgh, James J., additional, Boruchov, Adam, additional, Bhutani, Manisha, additional, Usmani, Saad Z., additional, Matous, Jeffrey V., additional, Yee, Andrew J., additional, Jakubowiak, Andrzej, additional, Paba-Prada, Claudia E., additional, Prescott, Julia, additional, Laubach, Jacob P., additional, Manier, Salomon, additional, Nadeem, Omar, additional, Richardson, Paul G., additional, Badros, Ashraf Z., additional, Trippa, Lorenzo, additional, Mateos, Maria-Victoria, additional, Getz, Gad, additional, and Ghobrial, Irene M., additional

Published
2021
Full Text
View/download PDF

220. A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Author

Paul, Barry, primary, Liedtke, Michaela, additional, Monge, Jorge, additional, Chaudhry, Maria, additional, Rifkin, Robert M., additional, Gandhi, Mitul D., additional, Khouri, Jack, additional, Kin, Andrew, additional, Kovacsovics, Tibor, additional, Levy, Moshe Y., additional, Mohrbacher, Ann, additional, Schmidt, William, additional, Siegel, David S., additional, Silbermann, Rebecca W., additional, Byrne, Anna Louise, additional, Ncube, Tina, additional, Murphy, Michael, additional, Gu, Lin, additional, Rajakumaraswamy, Nishanthan, additional, Chao, Mark, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

221. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Author

Pasvolsky, Oren, primary, Yeshurun, Moshe, additional, Fraser, Raphael, additional, Estrada-Merly, Noel, additional, Rozovski, Uri, additional, Shargian-Alon, Liat, additional, Assal, Amer, additional, Banerjee, Rahul, additional, Bumma, Naresh, additional, Gale, Robert Peter, additional, Hagen, Patrick, additional, Holmberg, Leona, additional, Hossain, Nasheed M., additional, Lazarus, Hillard M., additional, Lee, Cindy, additional, Mian, Hira, additional, Miller, Kevin C., additional, Nathan, Sunita, additional, Nagler, Arnon, additional, Nishihori, Taiga, additional, Parrondo, Ricardo D., additional, Patel, Sagar, additional, Schroeder, Mark A., additional, Usmani, Saad Z., additional, Wang, Trent, additional, Wirk, Baldeep, additional, Kumar, Shaji, additional, Shah, Nina, additional, Qazilbash, Muzaffar H., additional, and D’Souza, Anita, additional

Published
2021
Full Text
View/download PDF

222. P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

Author

Mateos, María-Victoria, primary, Usmani, Saad Z., additional, Quach, Hang, additional, Dimopoulos, Meletios-Athanasios, additional, Fonseca, Rafael, additional, McFadden, Ian, additional, Yusuf, Akeem, additional, Khurana, Monica, additional, Obreja, Mihaela, additional, and Spencer, Andrew, additional

Published
2021
Full Text
View/download PDF

223. P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma

Author

Malek, Ehsan, primary, Kansagra, Ankit, additional, Costa, Luciano, additional, Usmani, Saad Z., additional, Vij, Ravi, additional, Kumar, Shaji, additional, Godby, Kelly, additional, Bal, Susan, additional, Cornell, Robert, additional, Kang, Yubin, additional, Umyarova, Elvira, additional, Giri, Smith, additional, Chhabra, Saurabh, additional, Callander, Natalie S., additional, Hari, Parameswaran, additional, and Liedtke, Michaela, additional

Published
2021
Full Text
View/download PDF

225. OAB-002: Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)

Author

Jakubowiak, Andrzej, primary, Kumar, Shaji, additional, Medhekar, Rohan, additional, Pei, Huiling, additional, Lefebvre, Patrick, additional, Kaila, Shuchita, additional, He, Jianming, additional, Lafeuille, Marie-Helene, additional, Cortoos, Annelore, additional, Londhe, Anil, additional, Mavros, Panagiotis, additional, Lin, Thomas, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

226. OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)

Author

Jagannath, Sundar, primary, Berdeja, Jesus G., additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam, additional, Madduri, Deepu, additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C., additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Pacaud, Lida, additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

227. OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study

Author

Moreau, Philippe, primary, Facon, Thierry, additional, Kumar, Shaji, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Bahlis, Nizar, additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, O’Dwyer, Michael, additional, Perrot, Aurore, additional, Venner, Christopher, additional, Weisel, Katja, additional, Mace, Joseph R., additional, Raje, Noopur, additional, Tiab, Mourad, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Pei, Huiling, additional, Tromp, Brenda, additional, Delioukina, Maria, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

228. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

Author

Jurczyszyn, Artur, Grzasko, Norbert, Gozzetti, Alessandro, Czepiel, Jacek, Cerase, Alfonso, Hungria, Vania, Crusoe, Edvan, Silva Dias, Ana Luiza Miranda, Vij, Ravi, Fiala, Mark A., Caers, Jo, Rasche, Leo, Nooka, Ajay K., Lonial, Sagar, Vesole, David H., Philip, Sandhya, Gangatharan, Shane, Druzd-Sitek, Agnieszka, Walewski, Jan, Corso, Alessandro, Cocito, Federica, Vekemans, Marie-Christine M., Atilla, Erden, Beksac, Meral, Leleu, Xavier, Davila, Julio, Badros, Ashraf, Aneja, Ekta, Abildgaard, Niels, Kastritis, Efstathios, Fantl, Dorotea, Schutz, Natalia, Pika, Tomas, Butrym, Aleksandra, Olszewska-Szopa, Magdalena, Usnarska-Zubkiewicz, Lidia, Usmani, Saad Z., Nahi, Hareth, Chim, Chor S, Shustik, Chaim, Madry, Krzysztof, Lentzsch, Suzanne, Swiderska, Alina, Helbig, Grzegorz, Guzicka-Kazimierczak, Renata, Lendvai, Nikoletta, Waage, Anders, Andersen, Kristian T., Murakami, Hirokazu, Zweegman, Sonja, and Castillo, Jorge J.

Published
2016
Full Text
View/download PDF

229. CD38-Directed Therapies for Management of Multiple Myeloma

Author

Hashmi,Hamza, Husnain,Muhammad, Khan,Ali, and Usmani,Saad Z

Subjects
ImmunoTargets and Therapy
Abstract

Hamza Hashmi,1 Muhammad Husnain,2 Ali Khan,3 Saad Z Usmani3 1Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA; 2Department of Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ, USA; 3Division of Plasma Cell Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USACorrespondence: Saad Z UsmaniClinical Research in Hematologic Malignancies, Levine Cancer Institute/Atrium Health, Charlotte, NC, USATel +1 980-442-4363Email saad.usmani@atriumhealth.orgAbstract: The survival outcomes for multiple myeloma have improved several-fold in the past two decades, primarily due to the introduction of therapies with novel mechanisms of action including immunomodulatory agents, proteasome inhibitors, stem cell transplant and monoclonal antibodies in the schema of therapy. Antibody-based therapies targeting the surface marker CD38, namely daratumumab and isatuximab, have emerged as being highly effective as single agents as well as in combination regimens for both newly diagnosed and relapsed settings. Herein, the authors summarize the most recent data with both the current and emerging CD38-directed therapies in multiple myeloma.Keywords: multiple myeloma, daratumumab, isatuximab, CD38, bispecific antibody, antibody drug conjugate

Published
2021

233. Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z., primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

234. Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z., primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

235. MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z., primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

236. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Author

Martin, Tom, primary, Usmani, Saad Z., additional, Schecter, Jordan M., additional, Vogel, Martin, additional, Jackson, Carolyn C., additional, Deraedt, William, additional, Tian, Hong, additional, Yeh, Tzu-min, additional, Banerjee, Arnob, additional, Pacaud, Lida, additional, Garrett, Ashraf, additional, Haltner, Anja, additional, Cameron, Chris, additional, Van Sanden, Suzy, additional, Diels, Joris, additional, Valluri, Satish, additional, and Samjoo, Imtiaz A., additional

Published
2021
Full Text
View/download PDF

240. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Author

Berdeja, Jesus G, primary, Madduri, Deepu, additional, Usmani, Saad Z, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D, additional, Stewart, A Keith, additional, Hari, Parameswaran, additional, Htut, Myo, additional, Lesokhin, Alexander, additional, Deol, Abhinav, additional, Munshi, Nikhil C, additional, O'Donnell, Elizabeth, additional, Avigan, David, additional, Singh, Indrajeet, additional, Zudaire, Enrique, additional, Yeh, Tzu-Min, additional, Allred, Alicia J, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Goldberg, Jenna D, additional, Schecter, Jordan M, additional, Deraedt, William, additional, Zhuang, Sen Hong, additional, Infante, Jeffrey, additional, Geng, Dong, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J, additional, Akram, Muhammad, additional, Hossain, Farah, additional, Rizvi, Syed, additional, Fan, Frank, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

241. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

Author

Hájek, Roman, primary, Minařík, Jiří, additional, Straub, Jan, additional, Pour, Luděk, additional, Jungova, Alexandra, additional, Berdeja, Jesus G, additional, Boccadoro, Mario, additional, Brozova, Lucie, additional, Spencer, Andrew, additional, van Rhee, Frits, additional, Vela-Ojeda, Jorge, additional, Thompson, Michael A, additional, Abonour, Rafat, additional, Chari, Ajai, additional, Cook, Gordon, additional, Costello, Caitlin L, additional, Davies, Faith E, additional, Hungria, Vania TM, additional, Lee, Hans C, additional, Leleu, Xavier, additional, Puig, Noemi, additional, Rifkin, Robert M, additional, Terpos, Evangelos, additional, Usmani, Saad Z, additional, Weisel, Katja C, additional, Zonder, Jeffrey A, additional, Bařinová, Magda, additional, Kuhn, Matyáš, additional, Šilar, Jiří, additional, Čápková, Lenka, additional, Galvez, Kenny, additional, Lu, Jin, additional, Elliott, Jennifer, additional, Stull, Dawn Marie, additional, Ren, Kaili, additional, and Maisnar, Vladimír, additional

Published
2021
Full Text
View/download PDF

242. Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations

Author

Maclachlan, Kylee H., Bagratuni, Tina, Kastritis, Efstathios, Ziccheddu, Bachisio, Lu, Sydney, Yellapantula, Venkata, Famulare, Chris, Argyropoulos, Kimon, Derkach, Andriy, Papaemmanuil, Elli, Dogan, Ahmet, Lesokhin, Alexander, Usmani, Saad Z., Landgren, C. Ola, Palomba, Lia M., Maura, Francesco, and Dimopoulos, Meletios A.

Abstract

The genomic landscape of Waldenström macroglobulinemia (WM) is characterized by somatic mutations in MYD88, present from the precursor stages. Using the comprehensive resolution of whole genome sequencing (WGS) in 14 CD19-selected primary WM samples; comparing clonal and subclonal mutations revealed that germinal center (GC) mutational signatures SBS9 (poly-eta) and SBS84 (AID) have sustained activity, suggesting that the interaction between WM and the GC continues over time. Expanding our cohort size with 33 targeted sequencing samples, we interrogated the WM copy number aberration (CNA) landscape and chronology. Of interest, CNA prevalence progressively increased in symptomatic WM and relapsed disease when compared with stable precursor stages, with stable precursors lacking genomic complexity. Two MYD88 wild-type WGS contained a clonal gain affecting chromosome 12, which is typically an early event in chronic lymphocytic leukemia. Molecular time analysis demonstrated that both chromosomal 12 gain events occurred early in cancer development whereas other CNA changes tend to occur later in the disease course and are often subclonal. In summary, WGS analysis in WM allows the demonstration of sustained GC activity over time and allows the reconstruction of the temporal evolution of specific genomic features. In addition, our data suggest that, although MYD88-mutations are central to WM clone establishment and can be observed in precursor disease, CNA may contribute to later phases, and may be used as a biomarker for progression risk from precursor conditions to symptomatic disease.

Published
2023
Full Text
View/download PDF

243. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Author

Chhabra, Saurabh, Callander, Natalie, Watts, Nicole L., Costa, Luciano J., Thapa, Bicky, Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Anderson, Larry D., Bal, Susan, Dhakal, Binod, Nathwani, Nitya, Shah, Nina, Medvedova, Eva, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Schmidt, Timothy, Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Dholaria, Bhagirathbhai, Cornell, R. Frank, Jerkins, James H., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Usmani, Saad Z., Richardson, Paul G., and Voorhees, Peter M.

Abstract

•Four cycles of daratumumab quadruplet induction had no major effect on stem cell yield.•Plerixafor use resulted in higher stem cell yield than use of granulocyte colony-stimulating factor alone.•In the MASTER and GRIFFIN studies, stem cell yield was adequate for autologous stem cell transplantation in nearly all patients.

Published
2023
Full Text
View/download PDF

244. Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Author

Paul, Barry, Minarík, Jirí, Cottini, Francesca, Gasparetto, Cristina, Khouri, Jack, Gandhi, Mitul, Hillengass, Jens, Levy, Moshe, Liedtke, Michaela, Manda, Sudhir, Sandhu, Irwindeep, Sborov, Douglas, Spicka, Ivan, Usmani, Saad Z, Gu, Lin, Robeson, Michelle, Murphy, Michael, Renard, Camille, Chen, Christine, and Pour, Luděk

Published
2023
Full Text
View/download PDF

245. Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Author

Hamadeh, Issam S., Shekarkhand, Tala, Rueda, Colin, Firestone, Ross, Wang, Alice, Korde, Neha, Hultcrantz, Malin, Lesokhin, Alexander, Mailankody, Sham, Hassoun, Hani, Shah, Urvi A, Maclachlan, Kylee H, Patel, Dhwani, Shah, Gunjan L., Scordo, Michael, Lahoud, Oscar Boutros, Chung, David, Landau, Heather, Giralt, Sergio A., Usmani, Saad Z, and Tan, Carlyn Rose

Published
2023
Full Text
View/download PDF

247. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

Author

Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, and Nooka, Ajay K.

Subjects
Adult, Cyclopropanes, Male, Acetates, Sulfides, Drug Administration Schedule, Discipline, Antineoplastic Agents, Immunological, Humans, Clinical Trials, Infusions, Intravenous, Drug Approval, Aged, Aged, 80 and over, Antibodies, Monoclonal, Original Articles, Middle Aged, daratumumab, Survival Analysis, United States, Injection Site Reaction, multiple myeloma, Treatment Outcome, montelukast, Quinolines, Original Article, Female, monoclonal antibodies, Neoplasm Recurrence, Local, CD38
Abstract

Background Daratumumab is a human CD38‐directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). Methods A multicenter, open‐label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent or if they were refractory to both a proteasome inhibitor and an immunomodulatory agent. Patients received daratumumab 16 mg/kg weekly for 8 weeks, every other week for 16 weeks, and monthly until they developed disease progression, unacceptable toxicity, or 60 days after the drug gained US approval. Treatment‐emergent grade ≥3 adverse events (AEs), serious AEs, and AEs of special interest were collected. Results Three hundred forty‐eight patients were enrolled at 39 US sites between June and December 2015. Patients received study therapy for a median of 1.9 months (range, 0.03‐6.0 months). Fifty‐two percent of patients transitioned to commercially‐available daratumumab and 37% discontinued because of progressive disease. Grade ≥3 AEs occurred in 50% of patients, including thrombocytopenia (15%) and anemia (14%). Serious AEs occurred in 35% of patients (12% were drug‐related), including infections (11%). Infusion reactions occurred in 56%, 2%, and 2% of patients during the first, second, and all subsequent infusions, respectively; respiratory symptoms (cough, dyspnea, throat irritation, nasal congestion) were common. The infusion reaction rate for the first infusion was 38% in 50 patients at 2 sites who received montelukast as premedication for their first infusion and 59% in patients who did not receive montelukast. Conclusions The current findings are consistent with previously reported trials and confirm the safety profile of daratumumab in heavily pretreated US patients who have relapsed or refractory MM. Cancer 2018;124:000‐000., An early access treatment protocol confirms the safety profile of daratumumab in patients with relapsed or refractory myeloma. Findings from 2 study sites (60 patients) that used montelukast premedication indicate reduced infusion reactions and infusion time associated with the first dose of daratumumab.

Published
2018

248. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Author

Terpos, Evangelos Mikhael, Joseph Hajek, Roman Chari, Ajai and Zweegman, Sonja Lee, Hans C. Mateos, Maria-Victoria and Larocca, Alessandra Ramasamy, Karthik Kaiser, Martin Cook, Gordon Weisel, Katja C. Costello, Caitlin L. Elliott, Jennifer Palumbo, Antonio Usmani, Saad Z.

Abstract

Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the ‘efficacy’ of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual’s composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting.

Published
2021

249. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Author

Terpos, Evangelos, Mikhael, Joseph, Hajek, Roman, Chari, Ajai, Zweegman, Sonja, Lee, Hans C., Mateos, Maria Victoria, Larocca, Alessandra, Ramasamy, Karthik, Kaiser, Martin, Cook, Gordon, Weisel, Katja C., Costello, Caitlin L., Elliott, Jennifer, Palumbo, Antonio, Usmani, Saad Z., Millennium Pharmaceuticals, and Takeda Pharmaceutical Company

Subjects
Quality of life, Cancer therapy, Adverse effects, Myeloma
Abstract

© The Author(s) 2021. Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the ‘efficacy’ of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual’s composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting. The authors acknowledge Steve Hill, Ph.D., of Ashfield MedComms, an Ashfield Health company, for professional medical writing support, which was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and complied with Good Publication Practice-3 (GPP3)104 guidelines, and Renda Ferrari, Ph.D. (Millennium Pharmaceuticals, Inc.) for contributing to the editorial and scientific content of the manuscript.

Published
2021

250. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Author

Weisel, Katja, Krishnan, Amrita, Schecter, Jordan M., Vogel, Martin, Jackson, Carolyn C., Deraedt, William, Yeh, Tzu-min, Banerjee, Arnob, Yalniz, Fevzi, Nesheiwat, Tonia, Sanden, Suzy Van, Diels, Joris, Valluri, Satish, Usmani, Saad Z., Berdeja, Jesus G., Jagannath, Sundar, and Martin, Tom

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results